Drug intelligence / Profile preview

obrutinib

Development stage: Preclinical
Lead developer: Pharmacyclics
Modality: Small Molecules
Administration: Oral

Overview

Obrutinib is a small molecule drug candidate that acts as a Bruton's tyrosine kinase (BTK) inhibitor. It is structurally and mechanistically related to ibrutinib, but it is a distinct compound. Obrutinib has been developed for the treatment of B-cell malignancies such as chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and other hematologic cancers. Like other BTK inhibitors, obrutinib works by irreversibly binding to the BTK enzyme, thereby blocking B-cell receptor signaling pathways essential for the survival and proliferation of malignant B cells.

Targets

EGFR (Epidermal growth factor receptor)BTK (Bruton tyrosine kinase)

Beyond the preview

Go deeper on obrutinib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on obrutinib.

Explore the full profile